ӳ��ý

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.

Tripp CS, Cuff C, Campbell AL, et al. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. Adv Ther. 2017;34(6):1364-1381. doi:10.1007/s12325-017-0525-8

Signal transduction in T lymphocytes using a conditional allele of Sos.

Holsinger LJ, Spencer DM, Austin DJ, Schreiber SL, Crabtree GR. Signal transduction in T lymphocytes using a conditional allele of Sos. Proc Natl Acad Sci U S A. 1995;92(21):9810-4.

Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.

Ferrer M, Kapoor TM, Strassmaier T, et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol. 1999;6(10):953-60. doi:10.1038/13324

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102(24):8567-72. doi:10.1073/pnas.0503221102

Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.

Bowers A, West N, Taunton J, Schreiber SL, Bradner JE, Williams RM. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J Am Chem Soc. 2008;130(33):11219-22. doi:10.1021/ja8033763

Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates.

Youngsaye W, Vincent B, Hartland CL, et al. Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates. Bioorg Med Chem Lett. 2011;21(18):5502-5. doi:10.1016/j.bmcl.2011.06.105

Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction.

Hu L, Magesh S, Chen L, et al. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg Med Chem Lett. 2013;23(10):3039-43. doi:10.1016/j.bmcl.2013.03.013

Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening.

Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001;276(42):38837-43. doi:10.1074/jbc.M106779200

Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays.

Kuruvilla FG, Shamji AF, Sternson SM, Hergenrother PJ, Schreiber SL. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature. 2002;416(6881):653-7. doi:10.1038/416653a

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Basarab GS, Kern GH, McNulty J, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep. 2015;5:11827. doi:10.1038/srep11827